🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMetabolic Health & DiabetesSURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — need advice Page 5

SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design — need advice

GenomicsKate Sat, Jan 3, 2026 at 11:59 AM 29 replies 1,587 viewsPage 5 of 6
LabKate
Senior Member
2,678
11,234
Jan 2024
Oregon
Jan 3, 2026 at 7:04 PM#21

+1 to KevinCompounds. Especially the point about "SURPASS-CVOT tirzepatide is not that str..." — I have seen the same in my own experience with SURPASS-CVOT tirzepatide.

46 2JenMemphis, pat_auckland, Dr.GastroMayo and 43 others
Reply Quote Save Share Report
DoseLogDan
Member
201
567
Feb 2025
Montana
Jan 3, 2026 at 7:21 PM#22

Yep. My endo said the same thing about SURPASS-CVOT.

43 23Dr.AddMedPHL, newstart_MO, mia_MS2 and 40 others
Reply Quote Save Share Report
TomFromTexas
Member
645
2,890
May 2024
Austin, TX
Jan 3, 2026 at 7:38 PM#23

+1 to jennifer_SEA. Especially the point about "The first 6 weeks are the hardest..." — I have seen the same in my own experience with SURPASS-CVOT tirzepatide.

41 20Dr.KarenChen, Dr.NateNeph, PharmD_Rodriguez and 38 others
Reply Quote Save Share Report
tyler_CSCS
Member
567
2,567
Jun 2024
Phoenix, AZ
Jan 3, 2026 at 7:55 PM#24

Following this thread closely. SURPASS-CVOT tirzepatide is something I'm actively working through.

36 8amy_econ_NJ, bbq_ray_KC, oliver_london and 33 others
Reply Quote Save Share Report
matt_MKE
Member
312
1,345
Sep 2024
Milwaukee, WI
Jan 3, 2026 at 8:12 PM#25

+1 to LabKate. Especially the point about "Especially the point about "SURPASS-CVOT..." — I have seen the same in my own experience with SURPASS-CVOT tirzepatide.

Last edited: Jan 3, 2026 at 11:12 PM
28 7DanielChem_CHI, marco_milano, pam_columbus and 25 others
Reply Quote Save Share Report

Similar Threads

SUSTAIN-6 to SELECT — the cardiovascular evidence timeline14 replies
GLP-1 and insulin resistance — HOMA-IR improvement data17 replies
Metabolic syndrome reversal criteria — how GLP-1 addresses all 55 replies
A1C target achievement rates — sema vs tirz comparison8 replies
SURPASS-CVOT: tirzepatide cardiovascular outcomes trial design3 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register